Navigation Links
Grove Instruments Inc. Closes $6 M Series B Financing
Date:12/19/2011

WORCESTER, Mass., Dec. 19, 2011 /PRNewswire/ -- Grove Instruments Inc., a medical device company based in Worcester, MA developing the world's first noninvasive glucometer, today announced that The Company's $6 M Series B Preferred Stock offering closed and was oversubscribed.  "The attractiveness of this financing has been catalyzed by our technical progress and recent additions of key individuals to our Board of Directors and Scientific Advisory Board," explained Arthur Combs, Grove's CEO.

During the fourth quarter, Grove added 2 recognized leaders in diabetes care and research with William Tamborlane, MD of Yale and David Harlan, MD of  the University of Massachusetts and formerly of NIH NIDDK both joining the Scientific Advisory Board.  Most recently, Craig Mello, Ph D, Nobel Laureate and molecular biologist joined Grove's Board of Directors to assist the company's advancement.  Dr. Mello has a child with Type 1 diabetes.  "We continue to assemble a world-class Board and an unparalleled complement of Scientific Advisors.  Investors invest in people before technology," says Combs, "and our corporate governance and leadership is second to none."

Grove's technology is also a tremendous draw for the investment community. "Diabetes is now nearly ubiquitous in day to day life," noted Combs, "nearly everyone knows someone with the disease and has seen the pain, cost and long term detriment of invasive glucose monitoring.  Our value proposition – painless, bloodless and no cost per use glucose monitoring – speaks for itself." Combs went on to say "Grove is on track to produce the world's first noninvasive glucose meter that exceeds the ISO standards for all of the current [invasive, blood-based] meters, and that is very exciting."

The private placement round was completed by new investors from the greater Boston area and current shareholders.  "In the end, we were actually oversubscribed for this round," Combs said, "the combination of great people and innovative transformational technology is truly compelling."

About Grove Instruments

Grove Instruments Inc. is a privately held pre-market medical device company developing the world's first noninvasive glucometer with the potential to exceed the ISO standard for blood glucose meters.  Grove's patented technology is based on the seminal concept of the Optical Bridge and is unique among all NIR spectroscopic approaches to noninvasive blood glucose determination.  The Company has been recognized for its innovation, technology development and clinical results on 10 separate occasions by the NIH NIDDK with funded SBIR Grants. In 2011, Grove was also recognized by the Massachusetts Life Sciences Center with an Accelerator Award – one of only 4 recipients out of all Boston-area life sciences companies applying in that round.  For more information see www.groveinstruments.com or contact Arthur Combs (314 341 3444 mobile).

Forward looking statement

Certain statements contained in this plan containing words like "believe", "intend", "may", "expect", "project" and other similar expressions are forward looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technological; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the company's filings.

Contact: Arthur Combs, CEO
Cell: 314 341 3444, acombs@groveinstruments.com

 


'/>"/>
SOURCE Grove Instruments Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mangrove Partners Responds to Erroneous CPEX Assertions
2. Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals, Inc.
3. Nobel Laureate to Join Grove Instruments Board of Directors
4. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
5. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
6. Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments
7. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
8. Verathon(R) Helps Physicians Identify the Presence of Abdominal Aortic Aneurysms with New AortaScan(TM) Brand of Portable Ultrasound Aortic Measurement Instruments
9. Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments
10. Millar Instruments and Harvard Apparatus Improve Ability to Provide Customers With Total Physiology Solutions Through Joint Distribution Agreement
11. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)... 2016   BIOTRONIK , a leader in ... and Drug Administration (FDA) approval of Iperia ProMRI ... failure patients with access to diagnostic magnetic resonance ... monitoring with daily automatic transmission and closed loop ... response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of ... and corporate training, and the National Military Family Association, a nonprofit that works ... the second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship ...
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food ... requiring e-cigarette manufacturers to submit their products through an arduous federal approval process. ... products that entered the market since February 15, 2007. That would essentially ban ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
(Date:5/5/2016)... Bremerton, WA (PRWEB) , ... May 05, 2016 , ... ... program serving the families of Bremerton, Port Orchard and communities west of Seattle. The ... Lowery, a 12 year local girl who died suddenly due to complications from the ...
Breaking Medicine News(10 mins):